Chemo-mixing robots placed in cancer hospital pharmacies and paid per dose
TL;DR Infusewright installs and runs robots that prepare intravenous chemotherapy doses inside hospital pharmacies, and charges per dose instead of a big upfront price. Mid-size cancer hospitals pay. The case rests on less wasted drug, fewer dosing errors and less cytotoxic exposure for pharmacy staff.
India had an estimated 1,562,099 new cancer cases in 2024[1], and many of those patients get intravenous chemotherapy mixed by hand. Hand mixing wastes expensive drug. At one Indian public tertiary hospital, 20.06% of procured chemotherapy was wasted, worth 17.14% of drug spend[2].
It also exposes staff. In a 2026 Chinese study, manual preparation left fluorouracil residue on gloves of up to 834 ng/cm², while a robot kept it near the detection limit[3]. And India has no specific national guideline for cytotoxic handling, according to a review that proposed one[4].
What it does, in regulatory terms: pharmacy automation for preparing prescribed doses. The robot does not decide doses. A pharmacist verifies every order and the hospital's pharmacy licence covers the compounding. Whether the robot itself needs a licence under the Medical Devices Rules is unclear, so confirm with CDSCO before you import[5].
Infusewright places a compounding robot in the hospital's clean room, connects it to the oncology order system and staffs or trains the operator. The robot weighs each dose, labels it and logs the record. Software groups patients' doses so open vials get used up before they expire, which is where most of the waste comes from. The hospital pays a fee per finished dose with a monthly minimum, so it skips a large capital purchase.
The seed spoke broadly of personalised medication. We narrowed it to chemotherapy, where dosing is already per patient and the case for robots is clearest.
Patients receive the doses but the buyer is the hospital - the head of pharmacy, the oncology director and the finance team. Mid-size private and trust cancer hospitals are the target, since the biggest centres can buy robots outright. The per-dose fee has to stay below the value of drug saved plus labour freed.
Evidence from comparable health systems has firmed up. Thailand's domestically built robot cost about twice as much per dose as hand mixing (THB 538 against THB 250), yet it produced a positive benefit-cost ratio of 1.566, which rose to 3.018 when it also served a network hospital[6]. Rising cancer volumes and costlier drugs make waste a bigger line item every year[1][2].
There's no public figure for India's pharmacy-automation market. Two narrower signals help - the 2024 estimate of 1.56 million new cancer cases[1], and measured waste of about one-fifth of drug procured at one hospital[2]. The Thai break-even of 41,802 robotic doses[6] tells you a site needs high volume. Treat these as inputs to your own model.
One US pharmacy-automation company sells IV room stations and workflow software[7], and several European and US firms make compounding robots, sold mostly as capital equipment. In Thailand a cancer hospital built its own robot[6]. We found no Indian company offering compounding robots on a per-dose model, and no Indian robot maker in this niche.
| Difficulty | Hard (60/100) |
| Starting capital | ₹3–5.5 Cr |
| Time to launch | 12–18 months |
The robots are imported and costly, and their payback depends on dose volume you don't control. Clean-room integration, pharmacist training and validation take months per site. Sales need the pharmacy head, the oncologists and finance to agree, and the robot's regulatory position needs written clarity.
Yes, this is regulated, and the robot's own status is still an open question.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
AI must never set or change a dose. Dosing stays with the oncologist and the verifying pharmacist, and the robot only prepares what they approve.
Want to work out the AI layer for Infusewright? Talk to Yash →
This suits a founder with hospital pharmacy or medical-equipment leasing experience and access to patient capital. I wouldn't try it as a first-time founder without hospital relationships. First prove, with one hospital's real order data, that daily dose volume and waste savings cover a per-dose fee.
Expect roughly ₹3–5.5 Cr, mostly for imported robots, clean-room integration and the months of validation at each site.
Compounding runs under the hospital's pharmacy licence, but the robot may need a CDSCO device or import licence. Get that answer in writing before you import.
Only at high volume. A Thai study put break-even at 41,802 robotic doses, so a site has to prepare enough doses every day for the fee to cover the robot.
The free Infusewright validation kit has the line-by-line capital breakdown, the effort scoring, the rules checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for pharmacy heads and oncologists, and 5 assumptions to test. Download the kit →
Thinking about building Infusewright or something close to it? The make-or-break work is finding sites with enough daily doses to pay for a robot, and I can help you run those numbers before you sign anything. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.